KemPharm (KMPH), Acura Pharma (ACUR) Enter Aversion Tech Licensing Agreement

October 18, 2016 6:31 AM EDT
Get Alerts KMPH Hot Sheet
Trade KMPH Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

KemPharm, Inc. (Nasdaq: KMPH) and Acura Pharmaceuticals, Inc. (Nasdaq: ACUR) announced that they have entered into a License Agreement (the "Agreement") whereby Acura will provide its proprietary Aversion Technology to KemPharm to use with its current and in-development immediate release (IR) opioid product candidates. Aversion® Technology is a patented composition of commonly used active and inactive pharmaceutical ingredients providing abuse deterrent features (ADF) and benefits for orally administered pharmaceutical drug products.

The Agreement provided for an upfront cash payment of $3.5 million to Acura at execution and grants KemPharm development and commercialization rights for up to three IR product candidates containing two of KemPharm’s opioid prodrugs. Additional payments are provided in the Agreement should KemPharm exercise its option to use Acura’s Aversion® Technology with more than the three products. Acura is eligible to receive a royalty at a low single-digit rate based on commercial sales by KemPharm of all products developed under the Agreement. KemPharm will solely own the intellectual property resulting from any new product development.

“Acura’s Aversion® Technology, an FDA-approved aversive ADF approach without a food effect, and KP201/IR, our priority lead product candidate, together offer significant potential benefits,” stated Travis C. Mickle, Ph.D., President and Chief Executive Officer of KemPharm. “We believe today’s Agreement will help us bridge the regulatory approval process between current abuse deterrence products and the ability of our new molecular entity prodrugs to demonstrate their ADF properties.”

“Based on the strength of our existing data, as well as what we view to be favorable developmental, regulatory and market conditions, we expect this agreement with Acura to allow us to bring a unique prodrug product with the addition of demonstrated aversive barriers to the market in the near term,” Mickle continued. “Access to this technology was contemplated in the guidance for timelines we recently provided for KP201/IR.”

"We are excited to partner with KemPharm who, like us, is committed to address the problem of prescription opioid abuse,” said Bob Jones, President and CEO of Acura. “We believe KemPharm shares our objective of aggressively developing and bringing to the healthcare community new abuse deterrent IR opioid analgesics to treat pain.”

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Litigation, Management Comments

Add Your Comment